Yu Feng

发表

Emerging immunotherapy targets in lung cancer

Xingsheng Hu, Hao-Hua Zhu, Yu Feng, 2020, Chinese medical journal.

The optimal timing and courses of bevacizumab added to chemotherapy for non-squamous non-small cell lung cancer: revelations from the real-world experience in a single Chinese cancer center

Hui Yu, Jialei Wang, Hui-jie Wang, 2020, Annals of translational medicine.

Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis

Yu Feng, Y. Tao, Haizhu Chen, 2022, Cancer Immunology, Immunotherapy.

Immune checkpoint inhibitors combined with angiogenic inhibitors in the treatment of locally advanced or metastatic lung adenocarcinoma patients

Sheng Yang, Yu-tao Liu, Lin Lin, 2022, Cancer Immunology, Immunotherapy.

The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study

Xingsheng Hu, Hao-Hua Zhu, Yu Feng, 2022, Thoracic cancer.

DLX2 Is a Potential Immune-Related Prognostic Indicator Associated with Remodeling of Tumor Microenvironment in Lung Squamous Cell Carcinoma: An Integrated Bioinformatical Analysis

Yu Feng, Liling Huang, T. Xie, 2022, Disease markers.

Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis

Yu Feng, Y. Tao, Haizhu Chen, 2022, Investigational New Drugs.

Immune checkpoint inhibitors combined with angiogenic inhibitors in the treatment of locally advanced or metastatic lung adenocarcinoma patients

Sheng Yang, Yu-tao Liu, Lin Lin, 2022, Cancer Immunology, Immunotherapy.

Programmed Death Ligand 1 Expression in Paired Non–Small Cell Lung Cancer Tumor Samples

Y. Shim, M. Dolled-Filhart, K. Emancipator, 2017, Clinical lung cancer.

Circulating tumor cells (CTCs)/circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer: Predictors for response and prognosis

P. Xing, Yuankai Shi, Xingsheng Hu, 2021, Thoracic cancer.

Different responses to anti-programmed cell death protein 1 (PD-1) immunotherapy in a patient with Lynch syndrome and metachronous urothelial and colon cancer: A case report

Xingsheng Hu, Rongrong Chen, Yu Feng, 2019, Oncology letters.

Decreased expression of RPS15A suppresses proliferation of lung cancer cells

Jian-hua Chang, Jialei Wang, Xin-min Zhao, 2015, Tumor Biology.

Incidence, survival comparison, and novel prognostic evaluation approaches for stage iii-iv pulmonary large cell neuroendocrine carcinoma and small cell lung cancer

Yu Feng, Liling Huang, T. Xie, 2023, BMC Cancer.

Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysis.

Yu Feng, Liling Huang, Y. Tao, 2023, Immunotherapy.

Investigation on the potential of circulating tumor DNA methylation patterns as prognostic biomarkers for lung squamous cell carcinoma

P. Xing, Yuankai Shi, A. Lizaso, 2020, Translational lung cancer research.

A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer

Hui Yu, Jian-hua Chang, Jialei Wang, 2014, Cancer biology & therapy.

Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer: A phase II open-label clinical study

Hui Yu, Jian-hua Chang, Jialei Wang, 2019, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

The Feasibility of Using Biomarkers Derived from Circulating Tumor DNA Sequencing as Predictive Classifiers in Patients with Small-Cell Lung Cancer

P. Xing, Yuankai Shi, Zhijie Wang, 2021, Cancer research and treatment.

Efficacy and safety of immune checkpoint inhibitor rechallenge in non‐small cell lung cancer: A systematic review and meta‐analysis

Xingsheng Hu, Yu Feng, Y. Tao, 2023, Thoracic cancer.